Sun Pharma’s Ilumya Receives Australian Therapeutic Goods Administration (TGA) Approval for the Treatment of Moderate-to-Severe Plaque Psoriasis

 Sun Pharma’s Ilumya Receives Australian Therapeutic Goods Administration (TGA) Approval for the Treatment of Moderate-to-Severe Plaque Psoriasis

Sun Pharma’s Ilumya Receives Australian Therapeutic Goods Administration (TGA) Approval for the Treatment of Moderate-to-Severe Plaque Psoriasis

Shots:

  • TGA approval is based on P-III reSURFACE data (N=1862) i.e. (reSURFACE 1 and reSURFACE 2) assessing Ilumya 100mg vs PBO or etanercept, showing PASI 75 reduction in psoriasis severity and Physician’s Global Assessment (PGA) score clear or minimal @12wks. after two doses
  • Ilumya (tildrakizumab) 100mg is a SC injection administered q12w post 0 and 4 weeks’ initial dosage completion. A patient support program will be launched offering Illumya’s self-injection training by doctors, registered nurses, dose reminders, injection consumables and a patient support help line
  • Ilumya is approved by the US FDA and EU for the treatment of moderate-to-severe plaque psoriasis candidates for systemic therapy in Mar and Sep 2018 respectively

Click here to read full press release/ article | Ref: Sun Pharma | Image: Livemint

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post